Exploiting the enhanced permeability and retention effect for tumor targeting

Drug Discovery Today

Volumn 11, Issue 17-18, 2006, Pages 812-818

  Iyer, Arun K ^a   Khaled, Greish ^b   Fang, Jun ^a   Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BERAPROST; BRADYKININ; CARBON NANOTUBE; CHROMIUM 51; CYCLOOXYGENASE 2; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; GLYCERYL TRINITRATE; INDOMETACIN; IODINATED POPPYSEED OIL; METALLOPROTEINASE INHIBITOR; MITOMYCIN C; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROSOUREA; PIRARUBICIN; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; PROBIOTIC AGENT; PROSTAGLANDIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; AREA UNDER THE CURVE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLON CANCER; COLON CARCINOMA; DRUG ACCUMULATION; DRUG DESIGN; DRUG DIFFUSION; DRUG FORMULATION; DRUG PENETRATION; DRUG RESEARCH; DRUG RETENTION; DRUG SOLUBILITY; DRUG TARGETING; DRUG UPTAKE; GENE OVEREXPRESSION; HUMAN; IMMUNOMODULATION; LACTOBACILLUS; LUNG NON SMALL CELL CANCER; MACROMOLECULE; MAXIMUM TOLERATED DOSE; METASTASIS; MICELLE; MICELLIZATION; NATURAL KILLER T CELL; NONHUMAN; PATIENT COMPLIANCE; POLYMER PRODUCTION; QUALITY OF LIFE; REVIEW; SHELF LIFE; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TARGET CELL DESTRUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PERMEABILITY; POLYMERS;

EID: 33747762229     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.07.005     Document Type: Review

References (80)

1. Leaf C. Why we're losing the war on cancer (and how to win it). Fortune 149 (2004) 76-82, 84-86, 88
2. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumor tropic accumulation of proteins and antitumor agent SMANCS. Cancer Res. 46 (1986) 6387-6392
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
4. Skinner S., et al. Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 50 (1990) 2411-2417
5. Suzuki M., et al. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67 (1981) 663-669
6. Maeda H., and Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6 (1989) 193-210
7. Iwai K., et al. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 44 (1984) 2115-2121
8. Courtice F.C. The origin of lipoproteins in lymph. In: Mayerson H.S. (Ed). Lymph and Lymphatic system (1963), Charles C. Thomas, Springfield, IL 89-126
9. Greish K., et al. Enhanced permeability and retention (EPR) effect and tumor-selective delivery of anticancer drugs. In: Torchillin V.P. (Ed). Delivery of protein and peptide drugs in cancer (2006), Imperial College Press, London 37-52
10. Satchi-Fainaro R., et al. Polymer therapeutics for cancer: current status and future challenges. Adv. Polym. Sci. 193 (2006) 1-65
11. Lee B.S., et al. Polycefin, a new prototype of a multifunctional nanoconjugate based on poly (beta-l-malic acid) for drug delivery. Bioconjug. Chem. 17 (2006) 317-326
12. Noguchi Y., et al. Early phase of tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89 (1998) 307-314
13. Seymour L.W., et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31A (1995) 766-770
14. Maeda H., et al. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74 (2001) 47-61
15. Senger D.R., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
16. Rosenthal R.A., et al. Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 4 (1990) 53-59
17. Leung D.W., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
18. Wu J., et al. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58 (1998) 159-165
19. Maeda H., et al. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 33 (1996) 222-230
20. Matsumura Y., et al. Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79 (1988) 1327-1334
21. Maeda H., et al. Purification and identification of [hydroxypropyl 3] bradykinin in ascetic fluid from a patient with gastric cancer. J. Biol. Chem. 263 (1988) 16051-16054
22. Doi K., et al. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 77 (1996) 1598-1604
23. Wu J., et al. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn. J. Cancer Res. 92 (2001) 439-451
24. Maeda H., et al. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85 (1994) 331-334
25. Matsumura Y., et al. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79 (1988) 1327-1334
26. Matsumura Y., et al. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res. 82 (1991) 732-741
27. Wu J., et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int. J. Cancer 98 (2002) 29-35
28. Maeda H., et al. Kallikrein-kinin in infection and cancer. Immunopharmacology 43 (1999) 115-128
29. Plendl J., et al. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol. Chem. 381 (2000) 1103-1115
30. Strausser H.R., and Humes J.L. Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in balb/c mice. Int. J. Cancer 15 (1975) 724-730
31. Trevisani A., et al. Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by non-steroidal anti-inflammatory drugs. Br. J. Cancer 41 (1980) 341-347
32. 2 analogue beraprost sodium. J. Drug Target. 11 (2003) 45-52
33. Akaike T., et al. 8-nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 685-690
34. Sawa T., et al. Superoxide generation mediated by 8-nitroguanosine, a highly redox-active nucleic acid derivative. Biochem. Biophys. Res. Commun. 311 (2003) 300-306
35. Okamoto T., et al. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 276 (2001) 29596-29602
36. Stroh M., et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 11 (2005) 678-682
37. Kimura N.T., et al. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 40 (1980) 2061-2068
38. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46 (2001) 169-185
39. Fang J., et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 63 (2003) 3567-3574
40. Greish K., et al. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjug. Chem. 16 (2005) 230-236
41. Li C.J., et al. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67 (1993) 975-980
42. Satchi-Fainaro R., et al. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug. Chem. 14 (2003) 797-804
43. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
44. Yuan F., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
45. Guyton C., and Hall J.E. The body fluids and kidneys. In: Guyton C., and Hall J.E. (Eds). Textbook of Medical Physiology (2000), W.B. Saunders 358-382
46. Greish K., et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 42 (2003) 1089-1105
47. Hori K., et al. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn. J. Cancer Res. 91 (2000) 261-269
48. Sato K., et al. Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea. Jpn. J. Cancer Res. 88 (1997) 1199-1204
49. Maeda H., et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3 (2003) 319-328
50. Minko T., et al. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets 5 (2004) 389-406
51. Reddy R.K., et al. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54 (2002) 571-586
52. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19 (2001) 424-436
53. Maeda H., et al. Cancer selective macromolecular therapeutics: tailoring of an antitumor protein drug. In: Feeny R.E., and Whitaker J.R. (Eds). Protein tailoring for food and medical uses (1986), Marcel Dekker 352-382
54. Maeda H., et al. Tailor-making of protein drugs by polymer conjugation for tumor targeting, a brief review on SMANCS. J. Protein Chem. 3 (1984) 181-193
55. Oda T., et al. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc. Soc. Exp. Biol. Med. 181 (1986) 9-17
56. Suzuki F., et al. Interferon induction by SMANCS: a polymer-conjugated derivative of neocarzinostatin. Anticancer Res. 8 (1988) 97-103
57. Suzuki F., et al. Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin. Cancer Immunol. Immunother. 30 (1989) 97-104
58. Suzuki F., et al. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin. Cancer Res. 50 (1990) 3897-3904
59. Suzuki F., et al. Immunomodulating activities of orally administered SMANCS, a polymer-conjugated derivative of the proteinaceous antibiotic neocarzinostatin, in an oily formulation. Int. J. Immunopharmacol. 15 (1993) 175-183
60. Oda T., et al. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 244 (1989) 974-976
61. 2: Improved stability of SOD in vitro and in vivo. J. Bioact. Compat. Polym. 11 (1996) 169-190
62. Sahoo S.K., et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem. 13 (2002) 1031-1038
63. Greish K., et al. SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J. Control. Release 97 (2004) 219-230
64. Oka K., et al. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, SMANCS, in an oily formulation. Pharm. Res. 7 (1990) 852-855
65. Hirayama S., et al. Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Comparative study with neocarzinostatin. Jpn. J. Antibiot. 39 (1986) 815-822
66. Vicent M.J., and Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 24 (2006) 39-47
67. Tanaka T., et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 277 (2004) 39-61
68. Reddy L.H. Drug delivery to tumours: recent strategies. J. Pharm. Pharmacol. 57 (2005) 1231-1242
69. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003) 214-221
70. Graham M.L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55 (2003) 1293-1302
71. Hershfield M.S., et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N. Engl. J. Med. 316 (1987) 589-596
72. Shvedova A.A., et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J. Toxicol. Environ. Health A 66 (2003) 1909-1926
73. Muller J., et al. Respiratory toxicity of multi-wall carbon nanotubes. Toxicol. Appl. Pharmacol. 207 (2005) 221-231
74. Maki S., et al. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56 (1985) 751-757
75. Sawa T., et al. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. Cancer Res. 60 (2000) 666-671
76. Fang J., et al. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res. 62 (2002) 3138-3143
77. Vasey P.A., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5 (1999) 83-94
78. Harrington K.J., et al. Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development. Clin. Oncol. (R Coll Radiol) 12 (2000) 16-24
79. Maeda N., et al. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release 100 (2004) 41-52
80. Maeda N., et al. Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate. Bioorg. Med. Chem. Lett. 14 (2004) 1015-1017